Immune System
|

Prospective RSV booster strategy evaluation in patients with active haematological malignancies (PROTECT RSV)

Institution: University Hospital Cologne
Applicant: Sibylle Mellinghoff
Funding line:
Else Kröner Excellence Fellowships
Prospective RSV booster strategy evaluation in patients with active haematological malignancies (PROTECT RSV)

Patients with hematological and oncological malignancies are at increased risk of severe respiratory syncytial virus (RSV) infections. Despite the availability of effective vaccines, the durability of vaccine-induced protection in immunocompromised patients and the need for additional doses remain unclear. Preliminary data from our ongoing research indicate waning immune responses following primary vaccination.

In a multicenter, randomized, placebo-controlled trial, the scientists investigate the immunogenicity, durability, and safety of RSV booster vaccination. Twelve months after primary vaccination, participants receive an additional RSV vaccine dose or placebo. Comprehensive analyses of humoral, cellular, and mucosal immune responses, complemented by molecular profiling, aim to identify biomarkers associated with sustained vaccine-induced immunity.

The project aims to provide the scientific basis for individualized RSV booster strategies and improve protection against severe RSV infections in immunocompromised patients.